AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer

AstraZeneca Plc AZN released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) in unresectable hepatocellular carcinoma (HCC) patients who had not received prior systemic therapy and were not eligible for localized treatment.

At four years of follow-up, these latest data show that a single priming dose of Imjudp added to Imfinzi, called the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab), reduced the risk of death by 22% compared to Bayer AG BAYRY BAYZF Nexavar (sorafenib). 

Also Read: AstraZeneca Mulls China Business Unit Spin-Off Amid Geopolitical Tensions.

An estimated 25.2% of patients treated with the STRIDE regimen were alive at four years versus 15.1% for those treated with sorafenib. 

An ad-hoc exploratory analysis showed that the treatment effects of the STRIDE regimen versus sorafenib were consistent across all clinically relevant subgroups of patients, as well as those surviving at least three years, regardless of the underlying disease cause or other baseline demographics.

The safety profile of the STRIDE regimen was consistent with the known profiles of each medicine, and no new safety signals were observed with longer follow-ups. 

Imfinzi + Imjudo is approved for adults with advanced or unresectable HCC in the US, EU (in the 1st-line setting), Japan, and several other countries. 

Price Action: AZN shares are down 0.16% at $70.85 on the last check Thursday.